DNA plasmid manufacturer VGXI Inc. filed suit against a Chinese biotechnology company alleging the company stole proprietary technology through its collaboration with another drugmaker. 

The suit is the most recent development in VGXI’s ongoing dispute with Pennsylvania-based Inovio, a company that had sought to obtain the DNA company’s technology in 2020 to develop a COVID-19 vaccine, an effort that was ultimately unsuccessful.